Skip to content

Recursion Pharmaceuticals

US · RXRX #2649 by market cap Listed 2021
2.45 -0.27 -9.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership fell 10.1 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
62.75% -10.09pp
Institutions
382 -10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund49.20%
Public Company4.46%
VC/PE Fund3.95%
Individual/Insider2.55%
Hedge Fund2.52%
Sovereign Wealth Fund1.10%
Private Company0.93%
Insurance Company0.27%
Family Office/Trust0.48%
Government Pension Fund0.26%
Other34.77%

Top holders as of 2026-09-30

BlackRock 8.58% · 53.48M sh
ARK Investment Management LLC 7.18% · 44.75M sh
Vanguard Portfolio Management, LLC 5.74% · 35.81M sh
State Street Global Advisors 4.81% · 30.00M sh
Vanguard Capital Management, LLC 3.69% · 23.00M sh
Baillie Gifford 2.92% · 18.17M sh
Geode Capital Management, LLC 2.23% · 13.91M sh
SoftBank Group Corp. 2.19% · 13.64M sh
DCVC 2.18% · 13.62M sh
FMR 1.83% · 11.44M sh
UBS Asset Management 1.62% · 9.71M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 10 buys · 40 sells

NameRoleStake
Blake Borgeson Independent Director 0.96%
Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor 0.86%
Dean Li Director 0.52%
David Hallett Chief Scientific Officer 0.07%
Ben Taylor CFO & President of Recursion UK 0.05%
Najat Khan Chief Executive Officer 0.03%
Zavain Dar Independent Director 0.03%
Franziska Michor Independent Director 0.02%
Robert Hershberg Independent Director 0.01%
Elaine Sun Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-02 Blake Borgeson Independent Director Open Market Disposition -40,000 $3.88
2026-11-01 Fred Hassan Chair of the Board Other Acquisition +156,658 --
2026-10-05 Robert Hershberg Independent Director Derivative Exercise and Sale -25,000 $2.22–5.00
2026-10-05 Blake Borgeson Independent Director Automatic Disposition -50,000 $4.84
2026-09-30 Dean Li Director Other Acquisition +3,378 --
2026-09-30 Zavain Dar Independent Director Other Acquisition +4,607 --
2026-09-14 Ben Taylor CFO & President of Recursion UK Sale to Issuer -5,396 $3.41
2026-09-07 Najat Khan Chief Executive Officer Automatic Disposition -22,408 $3.52
2026-08-31 Blake Borgeson Independent Director Automatic Disposition -30,000 $3.34
2026-08-20 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -77,290 $3.39
2026-08-19 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -75,000 $3.40
2026-08-18 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.28
2026-08-17 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -26,806 $3.00
2026-08-16 Ben Taylor CFO & President of Recursion UK Sale to Issuer -25,018 $3.16
2026-08-16 David Hallett Chief Scientific Officer Sale to Issuer -26,657 $3.16
2026-08-16 Najat Khan Chief Executive Officer Sale to Issuer -80,498 $3.16
2026-08-12 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.31
2026-08-11 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -50,000 $3.37
2026-08-09 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.27
2026-08-06 Christopher Gibson Co-Founder, Former Chairman & Interim Executive Advisor Intent to Sell (Form 144) -100,000 $3.25

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.

Recursion Pharmaceuticals discussion 0 comments

Add a comment